Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.30 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL844622 | 0.76 | NISCH (0.39) | NISCH | |
| SCHEMBL4681860 | 0.75 | GSK3B (0.33) | — | |
| SCHEMBL2645525 | 0.73 | NISCH (0.34) | NISCH | |
| SCHEMBL29889443 | 0.71 | CHEK1 (0.41) | NISCHCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL3954850 | 0.71 | CHEK1 (0.41) | NISCHCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL8271401 | 0.71 | CHEK1 (0.41) | NISCHCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL19116619 | 0.71 | CHEK1 (0.41) | NISCHCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL1461391 | 0.71 | NISCH (0.33) | NISCH | |
| SCHEMBL1461219 | 0.71 | CHRNB2 (0.50) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL1254387 | 0.71 | HTR2A (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118201929-A | PROTAC compound, pharmaceutical composition containing same, and preparation method and application thereof | 广东弘烨医药科技有限公司 | 2024-06-14 | — | — | CN | claimed |
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-04-19 | — | — | US | claimed |
| EP-2432784-A1 | FUSED BICYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma, S.A. (BE) | 2012-03-28 | — | — | EP | claimed |
| WO-2010133836-A1 | FUSED BICYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2010-11-25 | — | — | WO | claimed |
| WO-2008098143-A2 | ANTIMICROBIAL COMPOUNDS AND METHODS OF USE | TRIUS THERAPEUTICS (US) | 2008-08-14 | — | — | WO | claimed |
| EP-1430048-A1 | 3-(ARYLAMINO)METHYLENE-1, 3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS | Allergan, Inc. (US) | 2004-06-23 | — | — | EP | claimed |
| WO-2004050621-A2 | INDOL DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | ALLERGAN, INC (US) | 2004-06-17 | — | — | WO | claimed |
| WO-2003027102-A1 | 3-(ARYLAMINO)METHYLENE-1, 3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2003-04-03 | — | — | WO | claimed |
| EP-1230235-A1 | COMPOUNDS WITH ANTIBACTERIAL AND ANTIPARASITIC PROPERTIES | New Pharma Research Sweden AB (SE) | 2002-08-14 | — | — | EP | claimed |
| WO-2001036408-A1 | COMPOUNDS WITH ANTIBACTERIAL AND ANTIPARASITIC PROPERTIES | NEW PHARMA RESEARCH SWEDEN AB (SE) | 2001-05-25 | — | — | WO | claimed |
| CN-118201929-A | PROTAC compound, pharmaceutical composition containing same, and preparation method and application thereof | 广东弘烨医药科技有限公司 | 2024-06-14 | — | — | CN | disclosed |
| US-20120214798-A1 | Novel Ethanediamone Hepcidine Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | US | disclosed |
| EP-2475643-A1 | NOVEL ETHANE DIAMINE HEPCIDIN ANTAGONISTS | VIFOR (INTERNATIONAL) AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-04-19 | — | — | US | disclosed |
| EP-2432784-A1 | FUSED BICYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma, S.A. (BE) | 2012-03-28 | — | — | EP | disclosed |
| US-6300330-B1 | BLOOD COAGULATION FACTOR X INHIBITORS AS ANTICOAGULANTS | ZENECA LIMITED (GB) | 2001-10-09 | — | — | US | disclosed |
| WO-2001036408-A1 | COMPOUNDS WITH ANTIBACTERIAL AND ANTIPARASITIC PROPERTIES | NEW PHARMA RESEARCH SWEDEN AB (SE) | 2001-05-25 | — | — | WO | disclosed |
| EP-0897912-A1 | Amidino derivatives useful as nitric oxide synthase inhibitors | G.D. SEARLE & CO. (US) | 1999-02-24 | — | — | EP | disclosed |
| US-5382661-A | Useful in treating spinal trauma, head injury, subarachnoid hemorrhage | THE UPJOHN COMPANY (US) | 1995-01-17 | — | — | US | disclosed |
| US-5382661-A | Useful in treating spinal trauma, head injury, subarachnoid hemorrhage | THE UPJOHN COMPANY (US) | 1995-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | PI4KA, PDPK1, PIK3CA | NISCH 2053/4885CHRNB2 2161/4885CHRNA4 2476/4885 |
| US-20120214798-A1 | Novel Ethanediamone Hepcidine Antagonists | HAMP, SLC40A1, FTH1 | NISCH 298/4885CHRNB2 4523/4885CHRNA4 4563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.